# OnCo record shr-a2102 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/shr-a2102/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "shr-a2102" ;
  schema:name "SHR-A2102"@en ;
  schema:description "SHR-A2102 is an experimental investigational agent whose form is not stated in the registry from Shanghai Hengrui Pharmaceutical in phase 3 trials for cervical cancer, non-small-cell lung cancer and head and neck squamous cell carcinoma, with its target not yet stated publicly."@en ;
  schema:url <https://onco.cc/drugs/shr-a2102/> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/search?intr=SHR-A2102> ;
  onco:status "phase-3" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "antibody-drug conjugate (ADC), per the sponsor's pipeline page; form not stated in the registry record" ;
  onco:cancers <https://onco.cc/cancers/cervical/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/head-and-neck/>, <https://onco.cc/cancers/urothelial/> ;
  onco:companies <https://onco.cc/companies/hengrui/> ;
  onco:trials <https://onco.cc/trials/nct07418749/>, <https://onco.cc/trials/nct06589778/>, <https://onco.cc/trials/nct07059221/>, <https://onco.cc/trials/nct06512051/>, <https://onco.cc/trials/nct07229729/>, <https://onco.cc/trials/nct07175220/>, <https://onco.cc/trials/nct06895928/>, <https://onco.cc/trials/nct06639347/>, <https://onco.cc/trials/nct06915142/>, <https://onco.cc/trials/nct07393542/>, <https://onco.cc/trials/nct06417554/>, <https://onco.cc/trials/nct06879145/>, <https://onco.cc/trials/nct06474468/>, <https://onco.cc/trials/nct06654440/> .